GSK, Amicus start phase-3 trial of Fabry disease drug
CRANBURY, N.J. — GlaxoSmithKline and Amicus Therapeutics have started a late-stage clinical trial for a drug to treat a rare genetic disorder, the companies said.
GSK and Amicus announced the start of a second phase-3 trial of Amigal (migalastat hydrochloride) for Fabry disease, a rare lysosomal storage disorder that affects between 5,000 and 10,000 people worldwide. The market for Fabry disease has long been dominated by Genzyme, a subsidiary of French drug maker Sanofi that makes the biologic drug Fabrazyme (agalsidase beta).
"In collaboration with GSK, we are pleased to announce the dosing of the first patient in study 012, the first phase-3 pivotal study to compare Amigal to [enzyme replacement therapy]," Amicus chairman and CEO John Crowley said.
GSK donates more than $1 million to fight HPV
LONDON — GlaxoSmithKline is making a donation that it said would give more than 10,000 girls and women access to human papillomavirus vaccination.
GSK announced that it would donate $1 million worth of Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant) to the Pink Ribbon Red Ribbon Partnership over the next five years, as well as $50,000 to support the program operations. The partnership is an initiative led by Susan G. Komen for the Cure, UNAIDS, the President’s Emergency Relief Plan for AIDS Relief and the George W. Bush Institute.
"We share the Pink Ribbon Red Ribbon Partnership’s commitment to identifying and developing innovative models that will effectively educate patients and healthcare providers in developing countries about cancer prevention," GSK SVP developing countries and marketing access Duncan Learmouth said. "It is a sad reality that each year, thousands of women are diagnosed with cervical cancer, a potentially preventable cancer."
Sabona of London introduces sleek, functional medical ID bracelets
SIKESTON, Mo. — A new line of medical identification bracelets has hit the market.
Sabona of London said that its medical ID bracelets combine style with functionality. The bracelets, which include men’s, women’s, and unisex versions, prominently display the Caduceus symbol on one of the bracelet links with a medical alert message of choice permanently engraved under that link. All three designs have a 1200 gauss magnet in every link and are available in small/medium (7-in.) and large/extra large (8 in.) sizes. Additionally, a free wallet card is included with each bracelet.
For more information, visit Sabona.com.